Anti-obesity drugs: status quo and recent advances / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 243-247, 2011.
Artigo
em Inglês
| WPRIM
| ID: wpr-341422
ABSTRACT
Obesity has become a major health problem worldwide. The prevalence and morbidity of obesity-related diseases including diabetes, hypertension, cerebro-cardiovascular diseases, and tumors also have remarkably increased. Treatment of obesity poses a challenge for clinicians. Anti-obesity treatment is helpful to improve and even reverse obesity-related complications. Diet control and physical exercises remain the predominant interventions for obese patients. Anti-obesity drugs can be considered in those who respond poorly to behavioral intervention or those who have developed obesity-related complications. The commonly used anti-obesity drugs include gastrointestinal lipase inhibitors and appetite suppressants. Glucagon-like peptide 1 has also been found to be effective in reducing body weight. Some more drugs are under development, which include selective 5-HT 2c agonist, β3 receptor agonist, and melanocortin receptor 4 agonist, may also be promising.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Depressores do Apetite
/
Fármacos Antiobesidade
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Peptídeo 1 Semelhante ao Glucagon
/
Obesidade
Limite:
Humanos
Idioma:
Inglês
Revista:
Acta Academiae Medicinae Sinicae
Ano de publicação:
2011
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS